CAMBRIDGE, Mass. – July 10, 2014 – Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 144 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). After nearly three years of follow up, results on the 6-minute walk test (6MWT) showed a decline in walking ability at a rate slower than would be expected based on available DMD natural history data.
Sarepta Therapeutics of Cambridge, Mass., has received word from the U.S. Food and Drug Administration (FDA) that the agency will consider an accelerated approval pathway for eteplirsen, an experimental drug the company is developing for boys and young men with Duchenne muscular dystrophy (DMD) who can potentially be treated by skipping of exon 51 of the dystrophin gene.
CHICAGO, April 14, 2014 – The Muscular Dystrophy Association, the largest nonprofit funder of neuromuscular disease research in the United States, has awarded funding for 38 new research grants totaling $3.6 million for the first year and $10.7 million over three years.The awards will be made to researchers seeking promising treatments and cures for muscle diseases within MDA's program.